David Horn Sells 7,309 Shares of Seer (NASDAQ:SEER) Stock

Seer, Inc. (NASDAQ:SEER) CFO David Horn sold 7,309 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $2.03, for a total transaction of $14,837.27. Following the sale, the chief financial officer directly owned 486,650 shares in the company, valued at approximately $987,899.50. This represents a 1.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Seer Trading Down 1.5%

NASDAQ SEER opened at $2.02 on Friday. The company has a fifty day simple moving average of $1.99 and a two-hundred day simple moving average of $1.89. The stock has a market cap of $111.06 million, a P/E ratio of -1.66 and a beta of 1.56. Seer, Inc. has a 12-month low of $1.55 and a 12-month high of $2.41.

Seer (NASDAQ:SEER) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.55 million. Seer had a negative net margin of 478.05% and a negative return on equity of 27.23%.

Institutional Trading of Seer

A number of hedge funds have recently modified their holdings of SEER. Nano Cap New Millennium Growth Fund L P acquired a new position in Seer in the fourth quarter valued at approximately $1,510,000. Corient Private Wealth LLC acquired a new stake in shares of Seer during the 4th quarter worth approximately $116,000. Quadrature Capital Ltd acquired a new stake in shares of Seer during the 4th quarter worth approximately $101,000. Barclays PLC increased its holdings in shares of Seer by 685.0% during the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after purchasing an additional 52,982 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Seer in the 4th quarter valued at $85,000. Hedge funds and other institutional investors own 75.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SEER. Canaccord Genuity Group initiated coverage on Seer in a research note on Monday, May 4th. They set a “buy” rating and a $4.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research note on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $4.00.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.